Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer.
Serum sex hormone binding globulin (SHBG) was measured in 21 pre and 39 postmenopausal women with advanced breast cancer before treatment and 1, 3, 6, 9 and 12 months after ovarian irradiation or during continuous administration of tamoxifen at a dose of 10 mg twice daily, respectively; some patients received additional prednisolone at a dose of 5 mg twice a day. Ovarian irradiation was associated with a 25% reduction in serum SHBG levels 3 to 6 months after treatment whilst patients on tamoxifen experienced a rise of about 80% in serum SHBG levels after 1 to 3 months. In postmenopausal women prednisolone markedly dampened the effect of tamoxifen, reducing a 80% rise to about 20%. There was no relationship between SHBG levels and response to treatment.
Wang
D Y
DY
Imperial Cancer Research Fund, London, United Kingdom.
Rubens
R D
RD
Clark
G M
GM
Moore
J W
JW
Bulbrook
R D
RD
D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008593:Menopause; D010053:Ovary / Q000528:radiation effects; D011239:Prednisolone / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use*
D012738:Sex Hormone-Binding Globulin; D013629:Tamoxifen; D011239:Prednisolone